- Zacks
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
- Simply Wall St.
Top Three US Stocks Estimated Below Intrinsic Value In June 2024
As of June 2024, the U.S. stock market presents a mixed landscape, with the Dow Jones advancing while sectors like semiconductors weigh heavily on the Nasdaq. Amidst these fluctuations, identifying stocks that are potentially undervalued becomes crucial for investors looking for opportunities that may not yet reflect their intrinsic worth in their current market prices.
- Investor's Business Daily
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
© 2024 Yahoo. All rights reserved.